Caracterización de CTCs
como marcador surrogado de tejido
Protein assays
Use/Applications
AR
(Nuclear/Cytopla
matic)
Target
identification/Pharmacody
namic
EGFR
Target identification
HER2
Target identification
IGF-1R
Target identification
M30 (CK-M30)
Pharmacodynamic
γH2AX
Pharmacodynamic
pHH3
Pharmacodynamic
Genomic assays
Use/Applications
AR
amplification Marker of resistance
pTEN
loss
Marker of resistance/Drug
combinations
TMPRSS2/ERG
Taxonomic classification
Myc
amplification
Tumor profiling
Composite CD45+
pHH3+
CK+ DAPI
Leukocyte
control
CTCs post-
tretament
CTCs pre-
tretament
Olmos, Barker, Sharma et al. Clin Cancer Res. 2011
Attard G et al.Cancer Res. 2009
